161 related articles for article (PubMed ID: 8919276)
1. The induction of cytotoxicity by a bispecific antibody against CEA positive cell line, in vitro.
Hideshima T; Iwasaki A; Baba M; Yamashita Y; Shirakusa T; Okada H
Surg Today; 1996; 26(2):83-8. PubMed ID: 8919276
[TBL] [Abstract][Full Text] [Related]
2. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
3. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
[TBL] [Abstract][Full Text] [Related]
4. In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.
Lehmann S; Perera R; Grimm HP; Sam J; Colombetti S; Fauti T; Fahrni L; Schaller T; Freimoser-Grundschober A; Zielonka J; Stoma S; Rudin M; Klein C; Umana P; Gerdes C; Bacac M
Clin Cancer Res; 2016 Sep; 22(17):4417-27. PubMed ID: 27117182
[TBL] [Abstract][Full Text] [Related]
5. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
6. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody.
Osada T; Hsu D; Hammond S; Hobeika A; Devi G; Clay TM; Lyerly HK; Morse MA
Br J Cancer; 2010 Jan; 102(1):124-33. PubMed ID: 19953093
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of cytotoxicity against a CEA positive cell line by the bispecific antibody OH1 using LAK cells from cancer-bearing patients.
Baba M; Hideshima T; Yamashita Y; Shirakusa T
Oncol Rep; 1998; 5(5):1141-6. PubMed ID: 9683825
[TBL] [Abstract][Full Text] [Related]
8. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.
Osada T; Patel SP; Hammond SA; Osada K; Morse MA; Lyerly HK
Cancer Immunol Immunother; 2015 Jun; 64(6):677-88. PubMed ID: 25742933
[TBL] [Abstract][Full Text] [Related]
9. Further characterization of cytotoxic T cells generated by short-term culture of human peripheral blood lymphocytes with interleukin-2 and anti-CD3 mAb.
Jacobs N; Greimers R; Mazzoni A; Trebak M; Schaaf-Lafontaine N; Boniver J; Moutschen MP
Cancer Immunol Immunother; 1996 Jul; 42(6):369-75. PubMed ID: 8830741
[TBL] [Abstract][Full Text] [Related]
10. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
Bacac M; Fauti T; Sam J; Colombetti S; Weinzierl T; Ouaret D; Bodmer W; Lehmann S; Hofer T; Hosse RJ; Moessner E; Ast O; Bruenker P; Grau-Richards S; Schaller T; Seidl A; Gerdes C; Perro M; Nicolini V; Steinhoff N; Dudal S; Neumann S; von Hirschheydt T; Jaeger C; Saro J; Karanikas V; Klein C; Umaña P
Clin Cancer Res; 2016 Jul; 22(13):3286-97. PubMed ID: 26861458
[TBL] [Abstract][Full Text] [Related]
11. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
12. G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells.
Anderson PM; Crist W; Hasz D; Carroll AJ; Myers DE; Uckun FM
Blood; 1992 Dec; 80(11):2826-34. PubMed ID: 1280479
[TBL] [Abstract][Full Text] [Related]
13. A mouse/human-chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes.
Kuwahara M; Kuroki M; Arakawa F; Senba T; Matsuoka Y; Hideshima T; Yamashita Y; Kanda H
Anticancer Res; 1996; 16(5A):2661-7. PubMed ID: 8917366
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2.
Haagen IA; Geerars AJ; de Lau WB; Bast BJ; de Gast BC
Blood; 1995 Jun; 85(11):3208-12. PubMed ID: 7538821
[TBL] [Abstract][Full Text] [Related]
15. Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC-independent cytotoxicity.
Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
Clin Exp Immunol; 1997 May; 108(2):352-7. PubMed ID: 9158110
[TBL] [Abstract][Full Text] [Related]
16. Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice.
Shalaby MR; Carter P; Maneval D; Giltinan D; Kotts C
Clin Immunol Immunopathol; 1995 Feb; 74(2):185-92. PubMed ID: 7828373
[TBL] [Abstract][Full Text] [Related]
17. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
Shen GL; Li JL; Vitetta ES
J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
[TBL] [Abstract][Full Text] [Related]
18. Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells.
Torisu-Itakura H; Schoellhammer HF; Sim MS; Irie RF; Hausmann S; Raum T; Baeuerle PA; Morton DL
J Immunother; 2011 Oct; 34(8):597-605. PubMed ID: 21904216
[TBL] [Abstract][Full Text] [Related]
19. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
20. Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells.
Ohta K; Yamaguchi Y; Shimizu K; Miyahara E; Toge T
Anticancer Res; 2002; 22(5):2597-606. PubMed ID: 12529970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
